Pharmacodynamic-Pharmacokinetic Integration as a Guide to Medicinal Chemistry

被引:24
|
作者
Gabrielsson, Johan [1 ,5 ]
Fjellstrom, Ola [2 ]
Ulander, Johan [2 ]
Rowley, Michael [3 ]
Van der Graaf, Piet H. [4 ]
机构
[1] AstraZeneca R&D, Discovery DMPK, S-43183 Molndal, Sweden
[2] AstraZeneca R&D, Lead Generat, S-43183 Molndal, Sweden
[3] AstraZeneca R&D, Med Chem, S-43183 Molndal, Sweden
[4] Pfizer Ltd, Sandwich Res Unit, Dept Pharmacokinet Dynam & Metab PDM & Global Pha, Sandwich CT13 9NJ, Kent, England
[5] AstraZeneca R&D, BAC, S-43183 Molndal, Sweden
关键词
Mechanism-based PKPD modelling; potency; efficacy; lipophilicity; structure-activity relationship; turnover models; effect compartment models; occupancy binding models; PLASMA-PROTEIN BINDING; PHARMACOLOGY; RATS; MODEL; TIME;
D O I
10.2174/156802611794480864
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system properties, enabling prediction of the magnitude and time course of drug responses under physiological and pathological conditions in animals and man. Since the pharmacological response generated by a drug is highly dependent on the actual system used to study its action, knowledge about its potency and efficacy at a given concentration or dose is insufficient to obtain a proper understanding of its pharmacodynamic profile. Hence, the output of PKPD activities extends beyond the provision of quantitative measures (models) of results, to the design of future protocols. Furthermore, because PKPD integrates DMPK (e. g. clearance) and pharmacology (e. g. potency), it provides an anchor point for compound selection, and, as such, should be viewed as an important weapon in medicinal chemistry. Here we outline key PK concepts relevant to PD, and then consider real-life experiments to illustrate the importance to the medicinal chemist of data obtained by PKPD. Useful assumptions and potential pitfalls are described, providing a holistic view of the plethora of determinants behind in vitro-in vivo correlations. By condensing complexity to simplicity, there are not only consequences for experimental design, and for the ranking and design of compounds, but it is also possible to make important predictions such as the impact of changes in drug potency and kinetics. In short, by using quantitative methods to tease apart pharmacodynamic complexities such as temporal differences and changes in plasma protein binding, it is possible to target the changes necessary for improving a compound's profile.
引用
收藏
页码:404 / 418
页数:15
相关论文
共 50 条
  • [41] Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis
    Sherwin, Catherine M. T.
    Zobell, Jeffery T.
    Stockmann, Chris
    McCrory, Bradley E.
    Wisdom, Millie
    Young, David C.
    Olson, Jared
    Ampofo, Krow
    Spigarelli, Michael G.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 (01) : 71 - 79
  • [42] Pharmacokinetic-Pharmacodynamic Correlation Analysis of Rhodiola crenulata in Rats with Myocardial Ischemia
    Jia, Zhixin
    Zou, Guoming
    Xie, Yongyan
    Zhang, Enning
    Yimingjiang, Mureziya
    Cheng, Xianlong
    Fang, Cong
    Wei, Feng
    PHARMACEUTICALS, 2024, 17 (05)
  • [43] Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs
    Dostalek, Miroslav
    Akhlaghi, Fatemeh
    Puzanovova, Martina
    CLINICAL PHARMACOKINETICS, 2012, 51 (08) : 481 - 499
  • [44] Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin
    Stockis, Armel
    van Lier, Jan Jaap
    Cawello, Willi
    Kumke, Thomas
    Eckhardt, Klaus
    EPILEPSIA, 2013, 54 (07) : 1161 - 1166
  • [45] Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel
    René Bruno
    Nicole Vivier
    Christine Veyrat-Follet
    Guy Montay
    Gerald R. Rhodes
    Investigational New Drugs, 2001, 19 : 163 - 169
  • [46] A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
    Cattrall, J. W. S.
    Asin-Prieto, E.
    Freeman, J.
    Troconiz, I. F.
    Kirby, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (12) : 2311 - 2321
  • [47] Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline
    Leng, Bing
    Yan, Genquan
    Wang, Cuicui
    Shen, Chengwu
    Zhang, Wen
    Wang, Wei
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 25 : 315 - 322
  • [48] Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa
    Dimova, Rositsa B.
    Talal, Andrew H.
    JOURNAL OF HEPATOLOGY, 2010, 53 (03) : 418 - 420
  • [49] Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis
    Autry, Elizabeth B.
    Rybak, Jeffrey M.
    Leung, Noelle R.
    Gardner, Brian M.
    Burgess, Donna R.
    Anstead, Michael I.
    Kuhn, Robert J.
    PHARMACOTHERAPY, 2016, 36 (01): : 13 - 18
  • [50] Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats
    Bertera, Facundo
    Di Verniero, Carla Andrea
    Mayer, Marcos Alejandro
    Chiappetta, Diego
    Buontempo, Fabian
    Polizio, Ariel Hector
    Taira, Carlos Alberto
    Hoecht, Christian
    XENOBIOTICA, 2012, 42 (02) : 206 - 219